Traphagen Investment Advisors’s VanEck Biotech ETF BBH Stock Holding History

Traphagen Investment Advisors’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-59,005	Closed	-$9.21M	–	164
2023 Q2	$9.21M	Sell	59,005 -69	-0.1%	-$11K	1.2%	15
2023 Q1	$9.58M	Sell	59,074 -229	-0.4%	-$37.1K	1.41%	14
2022 Q4	$9.47M	Sell	59,303 -3,709	-6%	-$588K	1.49%	12
2022 Q3	$8.87M	Buy	63,012 +2,769	+5%	+$419K	1.63%	15
2022 Q2	$8.78M	Buy	60,243 +2,494	+4%	+$371K	1.6%	16
2022 Q1	$9.36M	Buy	57,749 +55,385	+2,343%	+$8.97M	1.51%	16
2021 Q4	$448K	Buy	+2,364	New	+$456K	0.07%	84
2019 Q3	–	Sell	-49,188	Closed	-$6.34M	–	115
2019 Q2	$6.34M	Buy	49,188 +1,496	+3%	+$184K	1.69%	17
2019 Q1	$6.13M	Buy	+47,692	New	+$6.02M	1.73%	18

Other funds holding BBH

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CIG

Consolidated Investment Group Englewood, Colorado $1.15B AUM 55.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Traphagen Investment Advisors's BBH Position: Q3 2023 in Review

Traphagen Investment Advisors sold out of VanEck Biotech ETF (BBH) in Q3 2023, closing a stake of 59,005 shares — an estimated $9.21M sold.

Traphagen Investment Advisors first reported a position in BBH in Q1 2019 and held it in 9 quarters. The position peaked at $9.58M in Q1 2023. 110 funds tracked by Wall St. Rank hold BBH as of Q3 2023.

Traphagen Investment Advisors reported no remaining VanEck Biotech ETF position as of Q3 2023 after selling out during the quarter.
Traphagen Investment Advisors sold 59,005 VanEck Biotech ETF shares in Q3 2023, an estimated $9.21M.
Traphagen Investment Advisors first reported a position in VanEck Biotech ETF in Q1 2019 and held it in 9 quarters.
Traphagen Investment Advisors's VanEck Biotech ETF position peaked at $9.58M in Q1 2023.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q3 2023.

Based on Traphagen Investment Advisors's 13F filing for Q3 2023, filed 17 Jun 2024.